Back to News
Market Impact: 0.15
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Source: globenewswire.com
Healthcare & Biotech
The company said data from a pooled-dose group in the multiple ascending-dose portion of its clinical trial will be compared with a matched natural-history cohort. No efficacy, safety, or financial results were disclosed, limiting the immediate investment implication.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Oncologists Cheer Melanoma Data
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal